Peter Attia· MD
Also, rapa can be limited to mTORC1 inhibition with intermittent dosing (constant dosing hits mTORC1 and C2, the latter which we'd like avoid to the best of our knowledge today).
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Also, rapa can be limited to mTORC1 inhibition with intermittent dosing (constant dosing hits mTORC1 and C2, the latter which we'd like avoid to the best of our knowledge today).
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
at least with the tool that we currently have to block tor which is like rapamycin or rapidlog giving intermittent dosing may be beneficial giving constant dosing may cancel out the benefit
I think the reason if mtor 2 is its inhibition is toxic which we have published papers arguing it is the reason that I think it's actually quite tolerated is because you know in general this the amounts of of rapy used in the longevity studies are relatively modest um they probably still are somewhat intermittent even though a mouse is eating them right because of course it doesn't eat all the time unlike what we were doing experimentally where we were dosing rap M very high keeping it above you know a certain level and certainly in tissue culture it's 247 and you can imagine that once an mtor finds aor it's immune to rap M now so so as soon as one of those guys interact you're going to have an M torque 2 and you need very little M torque 2 to keep akt happy we we found that early on you only need probably 10 to 15% at least in cells and culture to keep akt happy so there's going to be escapers as soon as rap me goes below a certain amount there'll be escapers and you'll make an M torque too.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.